A Review on Medication Delivery Using Resealed Erythrocytes

Srilakshmi Yanamala

doi:10.37022/jis.v7i3.90

Yanamala Srilakshmi Priyadarshini Institute of Pharmaceutical Education and Research, 5th Mile, Pulladigunta, Guntur-522017.Andhra Pradesh, India.

DOI https://doi.org/10.37022/jis.v7i3.90

Abstract

Cellular carriers, out of all the carriers that are used to target medications to different bodily tissues, satisfy a number of requirements that are desirable in clinical applications. The most crucial of these is that the carrier and its breakdown products must be biocompatible. platelets, fibroblasts, hepatocytes, erythrocytes, and nano erythrocytes, among other cells. The main obstacles to a successful industrialization are the therapeutic agents' quality control, process validation, and production scalability. Re-sealed erythrocytes are a unique drug delivery method that is now needed to solve this issue and increase patient compliance and efficiency. The isolation of carrier erythrocytes, drug loading techniques, parameter characterization techniques, and clinical uses of resealed erythrocytes were discussed in this review. "Resealed erythrocytes" are carriers that are created after the cells are broken up and the medication is attached to them using a few different techniques. Businesses now have the chance to cover a wide range of ailments for which there are presently no effective medicines because they have already completed many of the crucial clinical phases.

Keywords: erythrocytes, hepitocytes, and fibroblasts, leuckocytes, platelets

References

1. Shavi GV, Doijad RC, Deshpande PB, Manvi F, Meka SR, Udupa N, Omprakash R, Dhirendra K. Erythrocytes as carrier for prednisolone: in vitro and in vivo evaluation. Pak J Pharm Sci. 2010 Apr 1;23(2):194-200.
https://pubmed.ncbi.nlm.nih.gov/20363699
2. Sawant KK, Soni HN, Murthy RS. Investigation on resealed erythrocytes as carriers for 5-fluorouracil. INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2001;63(2):105-9.
3. Kumar A, Verma M, Jha KK. Resealed Erythrocytes as a Carrier for Drug Targeting: A Review. The pharma innovation. 2012 Apr 1;1(2, Part A):8.
https://doi.org/10.1111/j.1365-2362.1986.tb01305.x
4. Suryasagar G, Bhargavi S, Kanakaiah B, Sowmya DK, Naresh M, Nama S, Rao CB. A review ON resealed erythrocytes. Int. J. Biol. Pharmaceut. Res.. 2013;4:290-6. http://www.ijbpr.com/doi/MjM4a2FsYWkxNDc4NTIzNjk=
5. Deepthi B, Varun D, Gopal PN, Rao CH, Sumalatha G. Super porous hydrogels–Supreme drug delivery. Research Journal of Pharmacy and Technology. 2011;4(8):1182-8.
6. Mitchell DH, James GT, Kruse CA. Bioactivity of electric field‐pulsed human recombinant interleukin‐2 and its encapsulation into erythrocyte carriers. Biotechnology and applied biochemistry. 1990 Jun;12(3):264-75.
7. Kiranmai M, Renuka P, Brahmaiah B, Chandu BR. Vitamin D as a promising anticancer agent.
8. Darghouth D, Koehl B, Heilier JF2011, et al. Alterations of red blood cell metabolome in overhydrated hereditary stomatocytosis. Haematologica. 96(12):1861–1865.
9. Tiffert T, Bookchin RM, Lew VL, Bernhardt I, Ellory JC. Red cell membrane transport in health and disease.
https://link.springer.com/book/10.1007/978-3-662-05181-8
10. Biagiotti S, Rossi L, Bianchi M, Giacomini E, Pierigè F, Serafini G, Conaldi PG, Magnani M. Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. Journal of controlled release. 2011 Sep 25;154(3):306-13.
11. Cremel M, Guérin N, Horand F, Banz A, Godfrin Y. Red blood cells as innovative antigen carrier to induce specific immune tolerance. International journal of pharmaceutics. 2013 Feb 25;443(1-2):39-49.
https://www.sciencedirect.com/science/article/abs/pii/S0378517313000082?via%3Dihub
12. Godfrin Y, Bertrand Y. L-asparaginase Introduced into Erythrocytes for the Treatment of Leukaemia (ALL). BioMedES. 2006;1(1):10-3.
13. De Windt TS, Niemansburg SL, Vonk LA, van Delden JM, Roes KC, Dhert WJ, Saris DB, Bredenoord AL. Ethics in musculoskeletal regenerative medicine; guidance in choosing the appropriate comparator in clinical trials. Osteoarthritis and cartilage. 2019 Jan 1;27(1):34-40. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-clinical-
aspects-related-tissue-engineered-products_en.pdf
14. Lewis DA, Alpar HO. Therapeutic possibilities of drugs encapsulated in erythrocytes. International journal of pharmaceutics. 1984 Dec 1;22(2-3):137-46.
15. Jaitely V, Kanaujia P, Venkatesan N, Jain S, Vyas SP. Resealed erythrocytes: drug carrier potentials and biomedical applications. Indian Drugs. 1996;33(12):589-94.
16. Jain S, Jain SK, Dixit VK. Erythrocytes based delivery of isoniazid: preparation and in-vitro characterization. Indian Drugs. 1995;32(10):471-6.